| C4X Stock | | | EUR 0.07 0.01 16.88% |
Director
Dr. Caroline Lemarchand serves as Preclinical RD Director, Member of the Executive Committee of Bioalliance Pharma SA since 2006. From 2002 to 2006, she served as Project Director in charge of developing new formulations for Bioalliance Pharma most advanced products. Previously, she worked at Hoechst Marion Roussel and Novartis Pharma. She is a Pharmacist and holds and a Doctor in Pharmaceutical Sciences. since 2006.
| Tenure | 18 years |
| Professional Marks | Ph.D |
| Phone | 33 1 45 58 76 00 |
| Web | https://www.onxeo.com |
Onxeo SA Management Efficiency
The company has return on total asset
(ROA) of
(0.1108) % which means that it has lost $0.1108 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.3966) %, meaning that it generated substantial loss on money invested by shareholders. Onxeo SA's management efficiency ratios could be used to measure how well Onxeo SA manages its routine affairs as well as how well it operates its assets and liabilities.
Onxeo SA has accumulated 9.91
M in total debt with debt to equity ratio
(D/E) of 0.31, which is about average as compared to similar companies. Onxeo SA has a current ratio of 3.77, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Onxeo SA until it has trouble settling it off, either with new capital or with free cash flow. So, Onxeo SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Onxeo SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Onxeo to invest in growth at high rates of return. When we think about Onxeo SA's use of debt, we should always consider it together with cash and equity.
Similar Executives
Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. Onxeo SA was incorporated in 1997 and is headquartered in Paris, France. ONXEO S operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 29 people. Onxeo SA (C4X) is traded on Frankfurt Exchange in Germany and employs 36 people.
Management Performance
Onxeo SA Leadership Team
Elected by the shareholders, the Onxeo SA's board of directors comprises two types of representatives: Onxeo SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Onxeo. The board's role is to monitor Onxeo SA's management team and ensure that shareholders' interests are well served. Onxeo SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Onxeo SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elisabeth Carstensen, Director of Alliance Management, Member of the Executive Committee | |
| Russell Greig, Independent Member of the Board | |
| Remi Droller, Member of the Board - Representative of Kurma Life Science Partners | |
| Daniele GuyotCaparros, Independent Member of the Board | |
| Michel Forest, Vice President Quality Qualified Person and Member of the Executive Committee | |
| Caroline Lemarchand, Preclinical R&D Director, Member of the Executive Committee | |
| Olivier Beaumont, Chief Medical Officer, Member of the Executive Committee | |
| Aude Michel, Director of Legal Affairs, Agreements and Licensing, Member of the Executive Committee | |
| Huiping Jiang, VP Assurance | |
| Sonia Vallons, Quality Assurance Director, Member of the Executive Committee | |
| Thomas Hofstaetter, Independent Member of the Board | |
| MD MPH, CEO Pres | |
| Delphine Lucas, Regulatory Affairs Director, Member of the Executive Committee | |
| Francoise Bono, Chief Scientific Officer, Member of the Executive Committee | |
| Nicolas Trebouta, Member of the Board - Permanent Representative of Financiere de la Montagne | |
| Audrey LegentilDumery, Director of Human Resources, Member of the Executive Committee | |
| Judith Greciet, Chief Executive Officer, Member of the Executive Committee, Member of the Board | |
| Nicolas Fellman, Vice President, Chief Financial Officer, Member of the Executive Committee | |
| David Solomon, Independent Member of the Board | |
| Joseph Zakrzewski, Non-Executive Chairman of the Board | |
| Louis Kayitalire, Vice President Head of Research & Development | |
| Philippe Maitre, Executive Vice President and Chief of U.S. Operations | |
| Nicolas Fellmann, CFO Director | |
Onxeo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Onxeo SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Onxeo Stock
Onxeo SA financial ratios help investors to determine whether Onxeo Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Onxeo with respect to the benefits of owning Onxeo SA security.